Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

ATLANTA, May 19, 2024 -- Virios Therapeutics, Inc. , a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including...

Related Keywords

New York ,United States , ,Prospectus Department ,Globenewswire Inc ,Company Or Virios Therapeutics ,Nasdaq ,Maxim Group ,Exchange Commission ,Virios Therapeutics Inc ,Securities Litigation Reform Act ,Virios Therapeutic ,Amended Annual Report ,